0 Комментарии
0 Поделились
518 Просмотры
0 предпросмотр
Спонсоры
Поиск
Знакомьтесь и заводите новых друзей
-
Войдите, чтобы отмечать, делиться и комментировать!
-
Resmetirom Approval Marks a Milestone in MASH TreatmentMetabolic Dysfunction-Associated Steatohepatitis (MASH), previously known as Nonalcoholic Steatohepatitis (NASH), represents a progressive form of metabolic liver disease closely linked to obesity, type 2 diabetes, and insulin resistance. This reclassification under the broader Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) framework reflects a shift toward understanding liver...0 Комментарии 0 Поделились 812 Просмотры 0 предпросмотр
-
U.S. Dominates Global MASH Therapy Landscape with 43% Market ShareThe North America Metabolic Dysfunction–Associated Steatohepatitis (MASH) Treatment Market is witnessing exponential growth, rising from USD 3.70 billion in 2024 to an anticipated USD 17.15 billion by 2033, at a strong compound annual growth rate (CAGR) of 19.3% from 2025 to 2033. This dynamic expansion is fueled by the increasing prevalence of obesity, Type 2 diabetes, aging population,...0 Комментарии 0 Поделились 855 Просмотры 0 предпросмотр
Спонсоры
© 2025 Friends - Best Social Network - החברים - רשת חברתית
Russian
